The FDA is concerned about the association of Multaq and liver injuries and said that Multaq’s new label will include a warning about these risks and a “Dear Doctor” letter is coming soon.
This adds to concern about whether there should be a Multaq recall. In draft guidance last year, the U.K. Health Institute said Multaq should only be considered as a treatment for patients who have not obtained a benefit from other medicines and that Multaq patients are at greater risk of having a heart attack because of conditions like diabetes or high blood pressure. This sentiment was also echoed by a Journal of the American College of Cardiology article.
Multaq is a medication for atrial fibrillation or atrial flutter, helping the heart beat normally. You would think that people at risk for atrial fibrillation or atrial flutter would be more likely to have or have had severe heart failure, but Multaq cannot be used in these patients.
I simply don’t know enough to say whether Multaq should be recalled. There are risks involved in almost every drug and the treatment of serious conditions often requires accepting certain risks. If you are on Multaq, the person you should be talking to in order to make a truly informed choice is your doctor. That said, the number of questions about this drug continues to rise.